Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Last Close
Dec 01 04:00PM ET
Dollar change
Percentage change
Index- P/E- EPS (ttm)-17.57 Insider Own83.95% Shs Outstand76.58M Perf Week20.56%
Market Cap1.79B Forward P/E- EPS next Y- Insider Trans0.00% Shs Float12.29M Perf Month272.02%
Income-44.24M PEG- EPS next Q- Inst Own0.18% Short Float / Ratio0.40% / 0.91 Perf Quarter243.08%
Sales0.00M P/S- EPS this Y- Inst Trans-1.54% Short Interest0.05M Perf Half Y575.32%
Book/sh-11.77 P/B- EPS next Y- ROA-215.90% Target Price45.00 Perf Year351.94%
Cash/sh0.03 P/C803.57 EPS next 5Y- ROE-269.01% 52W Range2.83 - 27.39 Perf YTD377.73%
Dividend- P/FCF- EPS past 5Y48.84% ROI-1257.95% 52W High-14.56% Beta2.03
Dividend %- Quick Ratio2.88 Sales past 5Y-70.71% Gross Margin-29.47% 52W Low726.71% ATR2.50
Employees7 Current Ratio2.88 Sales Q/Q- Oper. Margin0.00% RSI (14)74.66 Volatility19.25% 16.24%
OptionableNo Debt/Eq0.00 EPS Q/Q73.25% Profit Margin- Rel Volume1.80 Prev Close23.52
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume53.49K Price23.40
Recom2.00 SMA2072.59% SMA50144.66% SMA200297.27% Volume96,236 Change-0.51%
Date Action Analyst Rating Change Price Target Change
Apr-29-21Resumed Stephens Overweight $18 → $19
Feb-10-21Initiated Piper Sandler Overweight $15
May-21-20Initiated Raymond James Outperform $20
Jan-04-19Initiated Oppenheimer Outperform $24
Feb-12-18Reiterated B. Riley FBR, Inc. Buy $19 → $49
Feb-09-18Reiterated Chardan Capital Markets Buy $37.50 → $75
Feb-09-18Reiterated Chardan Capital Markets Buy $10 → $75
Dec-08-17Initiated B. Riley FBR, Inc. Buy $19
Jun-12-17Initiated Chardan Capital Markets Buy $10
Jun-06-17Initiated Ladenburg Thalmann Buy $11
Nov-13-23 07:00AM
Oct-30-23 12:00PM
Aug-23-23 12:36PM
Apr-03-23 09:01AM
Mar-29-23 10:13AM
08:00AM Loading…
Feb-28-23 08:00AM
Dec-27-22 07:00AM
Nov-16-22 05:05AM
Sep-19-22 09:43AM
Sep-01-22 04:05PM
Aug-25-22 08:00AM
Aug-23-22 07:11AM
Aug-19-22 08:00AM
Aug-15-22 04:05PM
Aug-11-22 06:00AM
12:46PM Loading…
Aug-10-22 12:46PM
Aug-03-22 08:00AM
Aug-01-22 08:30AM
Jul-22-22 12:21PM
Jul-19-22 08:00AM
Jul-14-22 09:40AM
Jul-06-22 08:00AM
Jun-29-22 08:00AM
Jun-28-22 09:40AM
May-26-22 11:03AM
May-23-22 09:57AM
May-09-22 08:30AM
Apr-08-22 09:57AM
08:00AM Loading…
Mar-31-22 08:00AM
Mar-15-22 05:00PM
Feb-17-22 08:00AM
Feb-03-22 05:38PM
Jan-25-22 08:00AM
Jan-12-22 12:00PM
Dec-20-21 07:51PM
Dec-11-21 11:59AM
Nov-22-21 08:00AM
Nov-12-21 09:54AM
Oct-29-21 08:00AM
Oct-28-21 03:05PM
Oct-13-21 04:05PM
Sep-28-21 04:01PM
Sep-24-21 08:00AM
Sep-17-21 07:06AM
Sep-15-21 08:00AM
Sep-09-21 08:00AM
Sep-08-21 08:00AM
Aug-05-21 10:55AM
Jul-29-21 03:05PM
Jul-22-21 08:00AM
Jul-19-21 04:01PM
Jul-14-21 08:00AM
Jul-06-21 08:00AM
Jul-01-21 08:00AM
Jun-28-21 08:45AM
Jun-21-21 06:00AM
Jun-10-21 08:00AM
May-20-21 02:57AM
May-18-21 08:00AM
May-13-21 08:00AM
May-06-21 12:19PM
May-05-21 12:29PM
Apr-28-21 08:00AM
Apr-21-21 11:43AM
Apr-19-21 08:00AM
Apr-12-21 08:00AM
Apr-07-21 04:05PM
Mar-21-21 04:20AM
Mar-04-21 08:00AM
Feb-18-21 08:00AM
Feb-11-21 04:01PM
Feb-10-21 10:05AM
Feb-03-21 08:00AM
Jan-29-21 04:01PM
Jan-27-21 08:00AM
Jan-26-21 04:04PM
Jan-20-21 08:00AM
Jan-19-21 11:46PM
Jan-15-21 08:00AM
Dec-15-20 10:28PM
Dec-07-20 08:00AM
Dec-03-20 04:02PM
Dec-02-20 08:00AM
Nov-30-20 10:44AM
Nov-25-20 10:15AM
Nov-24-20 04:01PM
Nov-12-20 08:50AM
Gyre Therapeutics, Inc. operates as a biopharmaceutical company. It is focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis). The company was founded on March 7, 1997 and is headquartered in San Diego, CA.